Hypoxia ameliorates brain hyperoxia and NAD

Autor: Robert M H, Grange, Rohit, Sharma, Hardik, Shah, Bryn, Reinstadler, Olga, Goldberger, Marissa K, Cooper, Akito, Nakagawa, Yusuke, Miyazaki, Allyson G, Hindle, Annabelle J, Batten, Gregory R, Wojtkiewicz, Grigorij, Schleifer, Aranya, Bagchi, Eizo, Marutani, Rajeev, Malhotra, Donald B, Bloch, Fumito, Ichinose, Vamsi K, Mootha, Warren M, Zapol
Rok vydání: 2020
Předmět:
Zdroj: Mol Genet Metab
ISSN: 1096-7206
Popis: Leigh syndrome is a severe mitochondrial neurodegenerative disease with no effective treatment. In the Ndufs4(−/−) mouse model of LS, continuously breathing 11% O(2) (hypoxia) prevents neurodegeneration and leads to a dramatic extension (~5-fold) in lifespan. We investigated the effect of hypoxia on the brain metabolism of Ndufs4(−/−) mice by studying blood gas tensions and metabolite levels in simultaneously sampled arterial and cerebral internal jugular venous (IJV) blood. Relatively healthy Ndufs4(−/−) and wildtype (WT) mice breathing air until postnatal age ~38 d were compared to Ndufs4(−/−) and WT mice breathing air until ~38 days old followed by 4-weeks of breathing 11% O(2). Compared to WT control mice, Ndufs4(−/−) mice breathing air have reduced brain O(2) consumption as evidenced by an elevated partial pressure of O(2) in IJV blood (P(ijv)O(2)) despite a normal PO(2) in arterial blood, and higher lactate/pyruvate (L/P) ratios in IJV plasma revealed by metabolic profiling. In Ndufs4(−/−) mice, hypoxia treatment normalized the P(ijv)O(2) and L/P ratios, and decreased levels of nicotinate in IJV plasma. Brain concentrations of nicotinamide adenine dinucleotide (NAD(+)) were lower in Ndufs4(−/−) mice breathing air than in WT mice, but preserved at WT levels with hypoxia treatment. Although mild hypoxia (17% O(2)) has been shown to be an ineffective therapy for Ndufs4(−/−) mice, we find that when combined with nicotinic acid supplementation it provides a modest improvement in neurodegeneration and lifespan. Therapies targeting both brain hyperoxia and NAD(+) deficiency may hold promise for treating Leigh syndrome.
Databáze: OpenAIRE